 Jed Lampe
Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytochrome P-450 CYP3A | 11 | 2023 | 60 | 3.530 |
Why?
| | Cytochrome P-450 Enzyme System | 11 | 2022 | 111 | 2.950 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 3 | 2021 | 17 | 1.780 |
Why?
| | Dehydroepiandrosterone Sulfate | 2 | 2023 | 44 | 1.010 |
Why?
| | Pharmaceutical Preparations | 3 | 2018 | 168 | 0.980 |
Why?
| | Fluorocarbons | 2 | 2023 | 100 | 0.910 |
Why?
| | Archaeal Proteins | 4 | 2015 | 49 | 0.900 |
Why?
| | Aloe | 1 | 2022 | 2 | 0.860 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2022 | 40 | 0.840 |
Why?
| | Fluoresceins | 1 | 2021 | 47 | 0.820 |
Why?
| | Lopinavir | 1 | 2021 | 29 | 0.790 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 178 | 0.780 |
Why?
| | Ritonavir | 1 | 2021 | 70 | 0.760 |
Why?
| | Growth and Development | 1 | 2019 | 6 | 0.710 |
Why?
| | Xenobiotics | 1 | 2019 | 25 | 0.700 |
Why?
| | Lanthanoid Series Elements | 1 | 2019 | 1 | 0.700 |
Why?
| | Pseudomonas aeruginosa | 1 | 2022 | 309 | 0.690 |
Why?
| | Biological Products | 1 | 2022 | 170 | 0.690 |
Why?
| | Premature Birth | 1 | 2023 | 284 | 0.680 |
Why?
| | Anti-Retroviral Agents | 1 | 2021 | 207 | 0.680 |
Why?
| | Chelating Agents | 1 | 2019 | 70 | 0.670 |
Why?
| | Octamer Transcription Factor-1 | 1 | 2018 | 4 | 0.670 |
Why?
| | Disease | 1 | 2019 | 87 | 0.660 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 80 | 0.650 |
Why?
| | Sulfolobus acidocaldarius | 3 | 2015 | 4 | 0.600 |
Why?
| | Ligands | 6 | 2018 | 565 | 0.580 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 2 | 2014 | 11 | 0.580 |
Why?
| | Cytochromes b5 | 1 | 2014 | 3 | 0.510 |
Why?
| | Organic Cation Transporter 1 | 1 | 2014 | 1 | 0.490 |
Why?
| | Testosterone | 2 | 2017 | 350 | 0.490 |
Why?
| | Heme | 3 | 2023 | 54 | 0.480 |
Why?
| | Iron | 3 | 2023 | 247 | 0.480 |
Why?
| | Methyltyrosines | 2 | 2010 | 3 | 0.430 |
Why?
| | Cystic Fibrosis | 1 | 2022 | 963 | 0.430 |
Why?
| | Serotonin | 1 | 2014 | 308 | 0.420 |
Why?
| | Oxazines | 2 | 2008 | 25 | 0.400 |
Why?
| | Molecular Docking Simulation | 2 | 2022 | 101 | 0.360 |
Why?
| | Kinetics | 4 | 2022 | 1623 | 0.360 |
Why?
| | Models, Molecular | 5 | 2018 | 1434 | 0.330 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2010 | 505 | 0.320 |
Why?
| | Protein Conformation | 4 | 2018 | 848 | 0.280 |
Why?
| | Antiviral Agents | 2 | 2022 | 653 | 0.280 |
Why?
| | Hepatocytes | 3 | 2016 | 204 | 0.260 |
Why?
| | Amino Acids | 1 | 2008 | 462 | 0.260 |
Why?
| | Protein Binding | 5 | 2018 | 1969 | 0.250 |
Why?
| | Oxidation-Reduction | 3 | 2021 | 935 | 0.240 |
Why?
| | Binding Sites | 5 | 2018 | 1221 | 0.240 |
Why?
| | HEK293 Cells | 2 | 2018 | 625 | 0.240 |
Why?
| | Substrate Specificity | 2 | 2018 | 369 | 0.230 |
Why?
| | Cysteine | 3 | 2012 | 184 | 0.230 |
Why?
| | Dehydroepiandrosterone | 1 | 2023 | 51 | 0.220 |
Why?
| | Cephalexin | 1 | 2022 | 9 | 0.220 |
Why?
| | Tretinoin | 1 | 2023 | 116 | 0.210 |
Why?
| | Arachidonic Acid | 1 | 2022 | 117 | 0.200 |
Why?
| | Humans | 16 | 2023 | 118268 | 0.200 |
Why?
| | Protease Inhibitors | 1 | 2022 | 101 | 0.200 |
Why?
| | Fatty Acids | 2 | 2022 | 403 | 0.190 |
Why?
| | Molecular Conformation | 1 | 2021 | 146 | 0.190 |
Why?
| | Base Sequence | 4 | 2019 | 2148 | 0.180 |
Why?
| | Drug Combinations | 1 | 2021 | 291 | 0.180 |
Why?
| | High-Throughput Screening Assays | 1 | 2021 | 122 | 0.180 |
Why?
| | Pseudomonas Infections | 1 | 2022 | 193 | 0.180 |
Why?
| | Birth Weight | 1 | 2023 | 463 | 0.180 |
Why?
| | Vasodilator Agents | 1 | 2022 | 328 | 0.180 |
Why?
| | Fluorescent Dyes | 1 | 2021 | 313 | 0.180 |
Why?
| | Water | 1 | 2023 | 422 | 0.180 |
Why?
| | Burns | 1 | 2023 | 247 | 0.180 |
Why?
| | Pentetic Acid | 1 | 2019 | 12 | 0.170 |
Why?
| | Infant, Newborn | 2 | 2021 | 5230 | 0.170 |
Why?
| | Click Chemistry | 1 | 2019 | 51 | 0.160 |
Why?
| | Copper | 1 | 2019 | 102 | 0.160 |
Why?
| | Spectrometry, Fluorescence | 3 | 2008 | 173 | 0.160 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 348 | 0.160 |
Why?
| | Principal Component Analysis | 1 | 2018 | 179 | 0.160 |
Why?
| | Hydroxylation | 1 | 2017 | 26 | 0.160 |
Why?
| | Microsomes, Liver | 1 | 2017 | 59 | 0.160 |
Why?
| | Biotransformation | 1 | 2017 | 52 | 0.150 |
Why?
| | Stereoisomerism | 1 | 2017 | 93 | 0.150 |
Why?
| | Transcriptome | 1 | 2023 | 752 | 0.150 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1997 | 139 | 0.150 |
Why?
| | Allosteric Regulation | 2 | 2007 | 85 | 0.150 |
Why?
| | Protein Transport | 1 | 2018 | 407 | 0.150 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2016 | 13 | 0.140 |
Why?
| | Catalytic Domain | 3 | 2015 | 206 | 0.140 |
Why?
| | Caprylates | 1 | 2016 | 25 | 0.140 |
Why?
| | Alkanesulfonic Acids | 1 | 2016 | 28 | 0.140 |
Why?
| | HIV-1 | 1 | 2021 | 772 | 0.130 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2007 | 482 | 0.130 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 3 | 2015 | 240 | 0.130 |
Why?
| | Crystallography, X-Ray | 3 | 2015 | 421 | 0.130 |
Why?
| | Neurotransmitter Agents | 1 | 2014 | 76 | 0.120 |
Why?
| | Serum Albumin | 1 | 2014 | 147 | 0.120 |
Why?
| | Gene Expression | 2 | 2016 | 1482 | 0.120 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2014 | 138 | 0.120 |
Why?
| | Pandemics | 1 | 2022 | 1338 | 0.120 |
Why?
| | Fetus | 1 | 2017 | 690 | 0.110 |
Why?
| | Liver | 1 | 2021 | 1803 | 0.110 |
Why?
| | Norepinephrine | 1 | 2014 | 212 | 0.110 |
Why?
| | Protein Isoforms | 1 | 2014 | 345 | 0.110 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2012 | 20 | 0.110 |
Why?
| | Receptors, Progesterone | 1 | 2014 | 325 | 0.110 |
Why?
| | Dopamine | 1 | 2014 | 249 | 0.100 |
Why?
| | Protein Folding | 1 | 2012 | 250 | 0.100 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2007 | 76 | 0.100 |
Why?
| | Pregnancy | 1 | 2023 | 5671 | 0.100 |
Why?
| | DNA | 1 | 1997 | 1385 | 0.090 |
Why?
| | Prospective Studies | 1 | 2022 | 6443 | 0.090 |
Why?
| | Lauric Acids | 1 | 2010 | 4 | 0.090 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2011 | 136 | 0.090 |
Why?
| | Spectrophotometry | 1 | 2010 | 52 | 0.090 |
Why?
| | Erythromycin | 2 | 2006 | 24 | 0.090 |
Why?
| | Catalysis | 1 | 2010 | 295 | 0.080 |
Why?
| | Acetaminophen | 1 | 2011 | 244 | 0.080 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2007 | 22 | 0.080 |
Why?
| | Bacteria | 2 | 2022 | 751 | 0.080 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2012 | 363 | 0.080 |
Why?
| | Biomarkers | 1 | 2017 | 3568 | 0.070 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 2006 | 4 | 0.070 |
Why?
| | Naphthalenesulfonates | 1 | 2006 | 7 | 0.070 |
Why?
| | HIV Infections | 1 | 2021 | 2454 | 0.070 |
Why?
| | Photoaffinity Labels | 1 | 2005 | 5 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2014 | 4044 | 0.070 |
Why?
| | Molecular Probe Techniques | 1 | 2005 | 9 | 0.070 |
Why?
| | Tryptophan | 1 | 2006 | 138 | 0.070 |
Why?
| | Quinolines | 1 | 2006 | 128 | 0.070 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2007 | 285 | 0.070 |
Why?
| | Barrett Esophagus | 1 | 2007 | 154 | 0.070 |
Why?
| | Progesterone | 1 | 2006 | 242 | 0.060 |
Why?
| | Models, Chemical | 1 | 2006 | 274 | 0.060 |
Why?
| | Esophageal Neoplasms | 1 | 2007 | 281 | 0.060 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2855 | 0.060 |
Why?
| | Adult | 2 | 2023 | 31327 | 0.060 |
Why?
| | Animals | 5 | 2023 | 33152 | 0.060 |
Why?
| | Cefadroxil | 1 | 2022 | 7 | 0.050 |
Why?
| | Cephalothin | 1 | 2022 | 7 | 0.050 |
Why?
| | Oxacillin | 1 | 2022 | 7 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 12 | 0.050 |
Why?
| | Cefazolin | 1 | 2022 | 19 | 0.050 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 338 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2461 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2022 | 301 | 0.050 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 822 | 0.050 |
Why?
| | Inflammation | 1 | 2011 | 2545 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2016 | 2657 | 0.050 |
Why?
| | Leishmania | 1 | 1999 | 2 | 0.040 |
Why?
| | Mutation | 1 | 2010 | 3435 | 0.040 |
Why?
| | RNA, Protozoan | 1 | 1999 | 57 | 0.040 |
Why?
| | Oligonucleotides, Antisense | 1 | 1999 | 99 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 394 | 0.040 |
Why?
| | Exons | 1 | 1999 | 306 | 0.040 |
Why?
| | Berberine Alkaloids | 1 | 1997 | 1 | 0.040 |
Why?
| | Chlorambucil | 1 | 1997 | 8 | 0.040 |
Why?
| | Alkylation | 1 | 1997 | 19 | 0.040 |
Why?
| | Base Composition | 1 | 1997 | 77 | 0.040 |
Why?
| | Male | 4 | 2017 | 57479 | 0.040 |
Why?
| | Guanosine | 1 | 1997 | 39 | 0.040 |
Why?
| | HLA-DQ beta-Chains | 1 | 1997 | 61 | 0.040 |
Why?
| | Guanine | 1 | 1997 | 74 | 0.040 |
Why?
| | Female | 2 | 2023 | 61268 | 0.040 |
Why?
| | Hydrolysis | 1 | 1997 | 176 | 0.040 |
Why?
| | Mice | 3 | 2023 | 15446 | 0.040 |
Why?
| | Time Factors | 1 | 2007 | 6368 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 1999 | 395 | 0.040 |
Why?
| | HLA-DQ Antigens | 1 | 1997 | 176 | 0.040 |
Why?
| | Cross-Linking Reagents | 1 | 1997 | 184 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2023 | 1590 | 0.040 |
Why?
| | Adenosine | 1 | 1997 | 211 | 0.030 |
Why?
| | Nucleic Acid Conformation | 1 | 1999 | 669 | 0.030 |
Why?
| | Amino Acid Substitution | 2 | 2006 | 275 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 333 | 0.030 |
Why?
| | Peptide Mapping | 1 | 2015 | 63 | 0.030 |
Why?
| | Structure-Activity Relationship | 2 | 2006 | 522 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2015 | 200 | 0.030 |
Why?
| | Protein Stability | 1 | 2015 | 163 | 0.030 |
Why?
| | Enzyme Activation | 2 | 2006 | 810 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 410 | 0.030 |
Why?
| | Imidazoles | 1 | 2015 | 227 | 0.030 |
Why?
| | Down-Regulation | 1 | 2016 | 623 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 862 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1514 | 0.030 |
Why?
| | Carbon Isotopes | 1 | 2012 | 115 | 0.030 |
Why?
| | Isotope Labeling | 1 | 2012 | 75 | 0.030 |
Why?
| | Galactosamine | 1 | 2011 | 4 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 1937 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1302 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 817 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 240 | 0.020 |
Why?
| | Endotoxins | 1 | 2011 | 234 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 559 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 256 | 0.020 |
Why?
| | Glutathione | 1 | 2011 | 324 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2011 | 213 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 2262 | 0.020 |
Why?
| | Ploidies | 1 | 2007 | 18 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2007 | 38 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2007 | 59 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 532 | 0.020 |
Why?
| | Enzyme Stability | 1 | 2006 | 75 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 1997 | 1967 | 0.020 |
Why?
| | Neutrophils | 1 | 2011 | 1142 | 0.020 |
Why?
| | Phenanthrenes | 1 | 2006 | 10 | 0.020 |
Why?
| | Phenylalanine | 1 | 2006 | 66 | 0.020 |
Why?
| | Aged | 1 | 2023 | 19599 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 641 | 0.020 |
Why?
| | Thermodynamics | 1 | 2006 | 391 | 0.010 |
Why?
| | Child | 1 | 2022 | 19033 | 0.010 |
Why?
| | Genotype | 1 | 2007 | 1870 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 4887 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2007 | 807 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2007 | 2491 | 0.010 |
Why?
| | Disease Progression | 1 | 2007 | 2477 | 0.010 |
Why?
| | Thionucleotides | 1 | 1999 | 34 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1999 | 508 | 0.010 |
Why?
| | Hot Temperature | 1 | 1999 | 333 | 0.010 |
Why?
| | Middle Aged | 1 | 2007 | 27514 | 0.000 |
Why?
|
|
Lampe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|